Related Experiment Videos
Modifying serum lipids to prevent coronary heart disease: do we have a consensus?
Insights
Treating high cholesterol (hyperlipidemia) can prevent heart disease, but benefits vary by patient factors. Careful risk-benefit analysis is crucial due to potential non-coronary risks.
Area of Science:
- Cardiology
- Preventive Medicine
- Pharmacology
Background:
- Hyperlipidemia is a significant independent risk factor for coronary heart disease.
- Recent trials show benefits of lipid-lowering interventions for coronary disease prevention.
- Unanswered questions persist regarding the comprehensive benefits and risks of hyperlipidemia treatment.
Discussion:
- Cholesterol reduction benefits are influenced by patient age, sex, and co-existing coronary risk factors.
- A small but consistent increase in non-coronary deaths is observed with cholesterol-lowering medications.
- This unexplained finding necessitates further investigation and careful risk-benefit assessment.
Key Insights:
- Individualized assessment of coronary disease risk is paramount.
- Potential long-term benefits of lipid modification must be weighed against potential harms.
- Identifying high-risk patients is essential for optimizing treatment outcomes.
Outlook:
- Further research is needed to elucidate the causes of non-coronary deaths associated with lipid-lowering drugs.
- Refined patient stratification strategies will improve the efficacy and safety of hyperlipidemia management.
- Personalized medicine approaches will guide the selection of patients most likely to benefit from cholesterol-lowering therapies.
Abstract:
Despite the importance of hyperlipidemia as an independent coronary risk factor and the positive results of recent lipid intervention trials to prevent coronary disease, there remain many unanswered questions regarding the benefits and risks of treating hyperlipidemia. Critical review of epidemiologic studies and clinical trials suggest that the benefits of cholesterol reduction may vary depending on the patient's age, sex, and the presence of other coronary risk factors. Furthermore, one must recognize that there is a small but consistent increase in noncoronary deaths among patients receiving cholesterol-lowering medications that remains unexplained but requires further evaluation. These data underscore the importance of weighing both the risks and benefits of modifying serum lipids. Accordingly, careful evaluation of the underlying risk of developing coronary disease and the potential long-term benefits of intervention are necessary to identify appropriate high-risk patients for treatment among whom the predicted benefits will outweigh the risks.